Physician profile
Sally Kim
NPI 1689635088
$1,392.23
in general payments reported to CMS, 2019-2025
15 companies · $729 in 2025
The $729 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $17.31 · 2023: $19.17 · 2024: $47.09 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $173.46 | 2019 | |
| Alcon Vision LLC | $149.48 | 2025 | Hydrus Microstent |
| Janssen Biotech, INC. | $132.83 | 2025 | Tremfya |
| Ucb, INC. | $129.30 | 2025 | Bimzelx |
| Allergan, INC. | $125.01 | 2019 | |
| Bausch & Lomb Americas INC. | $124.88 | 2025 | Miebo, Xiidra |
| Amgen INC. | $121.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.37 | 2019 | |
| Organogenesis INC. | $82.19 | 2025 | Via Matrix |
| Astellas Pharma US INC | $67.95 | 2024-2025 | Veozah |
| Novo Nordisk INC | $58.46 | 2020-2025 | Wegovy, Saxenda |
| Sun Pharmaceutical Industries INC. | $56.79 | 2019 | |
| Lilly USA, LLC | $48.49 | 2025 | Mounjaro, Zepbound |
| Galderma Laboratories, L.P. | $19.17 | 2023 | Dysport |
| Amag Pharmaceuticals, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.